title: European Cancer Congress 2015.
abstract: The European Cancer Congress, which attracts a range of European cancer groups, reflected intense interest in immunotherapies. we review key sessions, including three on the anti-programmed death-1 agent nivolumab, each in a different disease setting.
authors.forename: Walter
authors.initials: W
authors.lastname: Alexander